Open Nav

Please submit your session questions in advance at

OxSonics Limited

As a global leader in ultrasound-based drug delivery, OxSonics’ misssion is to maximise the potential of existing and emerging cancer therapies for the benefit of cancer patients world-wide. OxSonics Therapeutics proprietary platform, SonoTran, has been designed by clinicians for clinicians.

  • Date:Monday, February 11
  • Time:3:15 PM - 3:30 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23494
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Fund raising
  • Company
  • Company HQ City:Oxford
  • Company HQ Country:United Kingdom
  • Total Amount Raised to Date, in All Rounds:£15m
  • Size of Last Investment Round:£9.4m
  • CEO/Top Company Official:Dr Colin Story
  • Year Founded:2013
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:SonoTran
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Colin Story
OxSonics Limited